Ispinesib was the first KIF11 inhibitor to enter clinical trials and was reported to be well tolerated, but a lack of tumor response for ispinesib, and the other inhibitors that made it into clinical trials, has left the field with an overall disappointing outlook for clinical translation of KIF11 inhibitors. Here, KIF11 is linked to neoplasm.